Nasus Pharma (NSRX) Debt to Equity (2024)
Nasus Pharma (NSRX) posted Debt to Equity of -$0.56 for Q4 2024.
Nasus Pharma (NSRX) Debt to Equity (2024) Analysis & Trends
Nasus Pharma (NSRX) has reported Debt to Equity for 1 consecutive years, with -$0.56 the latest figure, recorded in Q4 2024.
- Debt to Equity for Q4 2024 came in at -$0.56, changed N/A year-over-year; the trailing twelve-month figure through Dec 2024 was -$0.56 (changed N/A YoY), and the FY2024 annual result was -$0.56, changed N/A from the prior year.
- Debt to Equity was -$0.56 for Q4 2024 at Nasus Pharma.
- Over five years, Debt to Equity peaked at -$0.56 in Q4 2024 and troughed at -$0.56 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 1.39 |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 0.68 |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | -9.70 |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 1.07 |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 6.24 |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 0.94 |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 0.72 |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Nasus Pharma | 28.20 Mn | 23.91 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | -0.56 |